Zaltrap Gets FDA Approval; Commercial Potential Mixed
By Jennifer Boggs
Monday, August 6, 2012
Regeneron Inc.'s Zaltrap (ziv-aflibercept) won FDA approval Friday in metastatic colorectal cancer, for use in combination with FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy, a little more than a year after surprising investors with positive data in a pivotal trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.